Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer

• DOI: 10.3747/co.26.4116
• Publication Date: 2019-03-05T18:47:21Z
• Authors: S.A. Laurie; S. Banerji; N. Blais; S. Brule; P.K. Cheema; P. Cheung; N. Daaboul; D. Hao; V. Hirsh; R. Juergens; J. Laskin; N. Leighl; R. MacRae; G. Nicholas; D. Roberge; J. Rothenstein; D.J. Stewart; M.S. Tsao
• Keywords: Clinical Practice; Best practice; Consensus conference

Background: Little evidence has been generated for how best to manage patients with non-small-cell lung cancer (NSCLS) presenting rarer clinical scenarios, including oligometastases, oligoprogression, and pseudoprogression. In each of those oncologists have consider balance efficacy quality life, while maximizing the duration line therapy ensuring that are still eligible later options, trial enrolment. Methods: An expert panel was convened define questions. Using case-based presentations, consensus practice recommendations scenario were through focused, evidence-based discussions. Results: Treatment strategies best-practice or presented, areas uncertainty identified. Conclusions: situation, treatment be tailored suit individual patient, but intent extending use treatment, keeping options in reserve lines therapy. Patient participation trials examining these issues should encouraged.